Monica NistÃ©r

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2999120/publications.pdf

Version: 2024-02-01

		87723	102304
103	4,872	38	66
papers	citations	h-index	g-index

107	107	107	7150
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2Î±. Brain, 2010, 133, 983-995.	3.7	401
2	p53 suppresses the self-renewal of adult neural stem cells. Development (Cambridge), 2006, 133, 363-369.	1.2	373
3	Human MIEF1 recruits Drp1 to mitochondrial outer membranes and promotes mitochondrial fusion rather than fission. EMBO Journal, 2011, 30, 2762-2778.	3.5	318
4	Platelet-derived growth factor in human glioma. Glia, 1995, 15, 257-263.	2.5	188
5	Human Fis1 regulates mitochondrial dynamics through inhibition of the fusion machinery. EMBO Journal, 2019, 38, .	3.5	187
6	The effect of platelet-derived growth factor on morphology and motility of human glial cells. Journal of Muscle Research and Cell Motility, 1983, 4, 589-609.	0.9	142
7	Rat Brain Capillary Endothelial Cells Express Functional PDGF B-Type Receptors. Growth Factors, 1989, 2, 1-8.	0.5	142
8	PDGF and PDGF receptors in glioma. Upsala Journal of Medical Sciences, 2012, 117, 99-112.	0.4	142
9	Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene, 1997, 15, 505-514.	2.6	129
10	Enhanced expression of transforming growth factor-Î² and its type-I and type-II receptors in human glioblastoma. International Journal of Cancer, 1995, 62, 386-392.	2.3	126
11	Transcription factor PROX1: its role in development and cancer. Cancer and Metastasis Reviews, 2012, 31, 793-805.	2.7	118
12	Molecular pathology in basal cell cancer with p53 as a genetic marker. Oncogene, 1997, 15, 1059-1067.	2.6	100
13	Regulation of Mammalian Mitochondrial Dynamics: Opportunities and Challenges. Frontiers in Endocrinology, 2020, 11, 374.	1.5	97
14	Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Research, 2020, 9, 63.	0.8	89
15	p53 -Dependent and -Independent Nucleolar Stress Responses. Cells, 2012, 1, 774-798.	1.8	85
16	Two distinctp53 immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis. , 1996, 69, 174-179.		80
17	A human glioma cell line secretes three structurally and functionally different dimeric forms of platelet-derived growth factor. FEBS Journal, 1988, 176, 179-186.	0.2	78
18	Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro-Oncology, 2010, 12, 19-27.	0.6	78

#	Article	IF	Citations
19	Activation of Neural and Pluripotent Stem Cell Signatures Correlates with Increased Malignancy in Human Glioma. PLoS ONE, 2011, 6, e18454.	1.1	75
20	Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. Neuro-Oncology, 2011, 13, 1178-1191.	0.6	75
21	Regulation of mitochondrial dynamics: convergences and divergences between yeast and vertebrates. Cellular and Molecular Life Sciences, 2013, 70, 951-976.	2.4	72
22	Expression of PDGF Î²-receptors in human meningioma cells. International Journal of Cancer, 1990, 46, 772-778.	2.3	71
23	Silencing of Ribosomal Protein S9 Elicits a Multitude of Cellular Responses Inhibiting the Growth of Cancer Cells Subsequent to p53 Activation. PLoS ONE, 2010, 5, e9578.	1.1	71
24	Expression of transforming-growth-factor (TGF)-? receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-?1. , 1999, 80, 756-763.		70
25	MIEF1/2 function as adaptors to recruit Drp1 to mitochondria and regulate the association of Drp1 with Mff. Scientific Reports, 2017, 7, 880.	1.6	64
26	The phosphorylation status of Ser-637 in dynamin-related protein 1 (Drp1) does not determine Drp1 recruitment to mitochondria. Journal of Biological Chemistry, 2019, 294, 17262-17277.	1.6	59
27	GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background. Glia, 2009, 57, 1143-1153.	2.5	57
28	Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model. Cancer Research, 2003, 63, 4305-9.	0.4	54
29	A COMPARISON BETWEEN STEM CELLS FROM THE ADULT HUMAN BRAIN AND FROM BRAIN TUMORS. Neurosurgery, 2008, 63, 1022-1034.	0.6	52
30	Loss of Nucleolar Histone Chaperone NPM1 Triggers Rearrangement of Heterochromatin and Synergizes with a Deficiency in DNA Methyltransferase DNMT3A to Drive Ribosomal DNA Transcription. Journal of Biological Chemistry, 2014, 289, 34601-34619.	1.6	51
31	Expression of PROX1 Is a Common Feature of High-Grade Malignant Astrocytic Gliomas. Journal of Neuropathology and Experimental Neurology, 2010, 69, 129-138.	0.9	47
32	Astrocytes enhance glioblastoma growth. Glia, 2020, 68, 316-327.	2.5	47
33	The novel conserved mitochondrial inner-membrane protein MTGM regulates mitochondrial morphology and cell proliferation. Journal of Cell Science, 2009, 122, 2252-2262.	1.2	44
34	Prognostic but not predictive role of plateletâ€derived growth factor receptors in patients with recurrent glioblastoma. International Journal of Cancer, 2011, 128, 1981-1988.	2.3	44
35	GABA-A Channel Subunit Expression in Human Glioma Correlates with Tumor Histology and Clinical Outcome. PLoS ONE, 2012, 7, e37041.	1.1	43
36	Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathologica, 2007, 113, 129-136.	3.9	42

#	Article	IF	Citations
37	The mitochondrial elongation factors MIEF1 and MIEF2 exert partially distinct functions in mitochondrial dynamics. Experimental Cell Research, 2013, 319, 2893-2904.	1.2	42
38	Frozen tissue biobanks. Tissue handling, cryopreservation, extraction, and use for proteomic analysis. Acta OncolÃ³gica, 2006, 45, 643-661.	0.8	41
39	A study of embryonic stem cellâ€related proteins in human astrocytomas: Identification of Nanog as a predictor of survival. International Journal of Cancer, 2014, 134, 1123-1131.	2.3	40
40	NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape. Scientific Reports, 2015, 5, 16495.	1.6	40
41	Platelet-derived growth factor-B and -C and active Î±-receptors in medulloblastoma cells. Biochemical and Biophysical Research Communications, 2002, 296, 604-611.	1.0	38
42	Protein Extraction from Solid Tissue. Methods in Molecular Biology, 2011, 675, 307-312.	0.4	34
43	Optimized protein extraction from cryopreserved brain tissue samples. Acta OncolÃ³gica, 2007, 46, 10-20.	0.8	33
44	Molecular genetics of human glioma. Current Opinion in Oncology, 1995, 7, 220-226.	1.1	31
45	PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro-Oncology, 2010, 12, 967-975.	0.6	31
46	Prominin-1 (CD133) Defines Both Stem and Non-Stem Cell Populations in CNS Development and Gliomas. PLoS ONE, 2014, 9, e106694.	1.1	30
47	SOX5/6/21 Prevent Oncogene-Driven Transformation of Brain Stem Cells. Cancer Research, 2017, 77, 4985-4997.	0.4	29
48	p53 must be competent for transcriptional regulation to suppress tumor formation. Oncogene, 2005, 24, 3563-3573.	2.6	28
49	Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors. Journal of Oncology, 2011, 2011, 1-11.	0.6	27
50	mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels. Cancer Biology and Therapy, 2014, 15, 1499-1514.	1.5	27
51	Molecular Genetic Analysis of p53 Intratumoral Heterogeneity in Human Astrocytic Brain Tumors. Journal of Neuropathology and Experimental Neurology, 2007, 66, 944-954.	0.9	26
52	A 1.8kb GFAP-promoter fragment is active in specific regions of the embryonic CNS. Mechanisms of Development, 2001, 107, 181-185.	1.7	25
53	Specific expression in mouse mesoderm- and neural crest-derived tissues of a human PDGFRA promoter/lacZ transgene. Mechanisms of Development, 1998, 70, 167-180.	1.7	23
54	Brain Abnormalities and Glioma-Like Lesions in Mice Overexpressing the Long Isoform of PDGF-A in Astrocytic Cells. PLoS ONE, 2011, 6, e18303.	1.1	21

#	Article	IF	Citations
55	Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Research, 2020, 9, 63.	0.8	21
56	Meta-analysis of cancer gene expression signatures reveals new cancer genes, SAGE tags and tumor associated regions of co-regulation. Nucleic Acids Research, 2010, 38, 7008-7021.	6.5	19
57	MIEF1/2 orchestrate mitochondrial dynamics through direct engagement with both the fission and fusion machineries. BMC Biology, 2021, 19, 229.	1.7	18
58	DLG3/SAP102 protein expression in malformations of cortical development: A study of human epileptic cortex by tissue microarray. Epilepsy Research, 2009, 84, 33-41.	0.8	16
59	EpCAM associates with endoplasmic reticulum aminopeptidase 2 (ERAP2) in breast cancer cells. Biochemical and Biophysical Research Communications, 2013, 439, 203-208.	1.0	15
60	Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells. SpringerPlus, 2016, 5, 1861.	1.2	15
61	Aberrant expression of genes associated with stemness and cancer in endometria and endometrioma in a subset of women with endometriosis. Human Reproduction, 2018, 33, 1924-1938.	0.4	15
62	Structural and functional aspects of platelet-derived growth factor and its role in the pathogenesis of glioblastoma. Molecular and Chemical Neuropathology, 1989, 10, 27-36.	1.0	14
63	Gene expression analyses of grade II gliomas and identification of rPTPÎ²/Î¶ as a candidate oligodendroglioma marker. Neuro-Oncology, 2008, 10, 2-9.	0.6	14
64	The Molecular Assembly State of Drp1 Controls its Association With the Mitochondrial Recruitment Receptors Mff and MIEF1/2. Frontiers in Cell and Developmental Biology, 2021, 9, 706687.	1.8	14
65	EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16997-17006.	3.3	13
66	Suppression of platelet-derived growth factor Î±- and Î²-receptor mRNA levels in human fibroblasts by SV40 T/t antigen. Journal of Cellular Physiology, 1996, 166, 12-21.	2.0	12
67	Reduced Expression of PROX1 Transitions Glioblastoma Cells into a Mesenchymal Gene Expression Subtype. Cancer Research, 2018, 78, 5901-5916.	0.4	12
68	VEGFR2 inhibition hampers breast cancer cell proliferation <i>via</i> enhanced mitochondrial biogenesis. Cancer Biology and Medicine, 2021, 18, 139-154.	1.4	12
69	SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma. Oncogene, 2021, 40, 5066-5080.	2.6	12
70	The spatial RNA integrity number assay for in situ evaluation of transcriptome quality. Communications Biology, 2021, 4, 57.	2.0	11
71	PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Oncotarget, 2016, 7, 72431-72442.	0.8	11
72	C/EBP is an essential component of PDGFRA transcription in MG-63 cells. Biochemical and Biophysical Research Communications, 2004, 315, 313-318.	1.0	10

#	Article	IF	Citations
73	Molecular cloning and characterization of two novel truncated isoforms of human Na+/Ca2+ exchanger 3, expressed in fetal brain. Gene, 2005, 348, 143-155.	1.0	10
74	RAD51 can inhibit PDGF-Bâ€“induced gliomagenesis and genomic instability. Neuro-Oncology, 2011, 13, 1277-1287.	0.6	10
75	Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas. Aging, 2021, 13, 3645-3660.	1.4	10
76	Operator Dependent Choice of Prostate Cancer Biopsy Has Limited Impact on a Gene Signature Analysis for the Highly Expressed Genes IGFBP3 and F3 in Prostate Cancer Epithelial Cells. PLoS ONE, 2014, 9, e109610.	1.1	10
77	Forced expression of platelet-derived growth factor B in the mouse cerebellar primordium changes cell migration during midline fusion and causes cerebellar ectopia. Molecular and Cellular Neurosciences, 2004, 26, 308-321.	1.0	9
78	Influence of MUC1 genetic variation on prostate cancer risk and survival. European Journal of Human Genetics, 2008, 16, 1521-1525.	1.4	9
79	MUC1 as a Putative Prognostic Marker for Prostate Cancer. Biomarker Insights, 2008, 3, BMI.S666.	1.0	8
80	Uncoupling of the ERÎ± regulated morphological phenotype from the cancer stem cell phenotype in human breast cancer cell lines. Biochemical and Biophysical Research Communications, 2011, 405, 581-587.	1.0	8
81	Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material. PLoS ONE, 2016, 11, e0145545.	1.1	8
82	Explaining the biological activity of transactivation-deficient p53 variants. Nature Genetics, 2006, 38, 395-396.	9.4	7
83	Identification of functionally distinct and interacting cancer cell subpopulations from glioblastoma with intratumoral genetic heterogeneity. Neuro-Oncology Advances, 2020, 2, vdaa061.	0.4	7
84	Whole Exome- and mRNA-Sequencing of an AT/RT Case Reveals Few Somatic Mutations and Several Deregulated Signalling Pathways in the Context ofSMARCB1Deficiency. BioMed Research International, 2015, 2015, 1-12.	0.9	6
85	Glycosylation controls sodium-calcium exchanger 3 sub-cellular localization during cell cycle. European Journal of Cell Biology, 2018, 97, 190-203.	1.6	5
86	Gli1 is not required for PdgfrÎ± expression during mouse embryonic development. Differentiation, 2005, 73, 109-119.	1.0	4
87	The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGFâ€Î²â€mediated growth regulation. Journal of Pathology, 2009, 219, 263-274.	2.1	4
88	Plateletâ€derived growth factor receptor Î±/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients. Glia, 2020, 68, 979-988.	2.5	4
89	Expression of Platelet-Derived Growth Factor Î² Receptor in Chondrogenesis of Perichondrial Transplants. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, 1995, 29, 289-295.	0.6	3
90	Identification and expression analysis of an N-terminally truncated isoform of human PDGF-C. Experimental Cell Research, 2008, 314, 2529-2543.	1.2	3

#	Article	IF	Citations
91	Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling. Journal of Neuro-Oncology, 2012, 107, 37-49.	1.4	3
92	Blood Plasma Handling for Protein Analysis. Methods in Molecular Biology, 2011, 675, 333-341.	0.4	3
93	The association between Annexin A2 and epithelial cell adhesion molecule in breast cancer cells. Cancer Reports, 2021, , e1498.	0.6	2
94	Handling of Solid Brain Tumor Tissue for Protein Analysis. Methods in Molecular Biology, 2011, 675, 327-332.	0.4	1
95	Gene expression biomarkers to predict overall survival of prostate cancer patients.. Journal of Clinical Oncology, 2012, 30, 4561-4561.	0.8	1
96	Abstract 2385: Understanding the dynamic interplay between genetically different cancer cell clones in glioblastoma. , 2016, , .		1
97	TMIC-24. ASTROCYTE-DEPENDENT ENHANCEMENT OF GLIOBLASTOMA GROWTH AS AÂCANDIDATE THERAPEUTIC TARGET. Neuro-Oncology, 2017, 19, vi248-vi248.	0.6	0
98	TMIC-35. ASTROCYTE-DEPENDENT ENHANCEMENT OF GLIOBLASTOMA GROWTH AS A CANDIDATE THERAPEUTIC TARGET. Neuro-Oncology, 2018, 20, vi263-vi264.	0.6	0
99	Abstract 5560: PROX1 expression and function in malignant gliomas. , 2012, , .		0
100	A gene expression signature to predicit overall, prostate cancer, and nonâ€“prostate cancer survival.. Journal of Clinical Oncology, 2013, 31, 51-51.	0.8	0
101	Abstract 3175: Discoveries from whole exome sequencing of medulloblastomas.. , 2013, , .		0
102	Abstract 2082: Control and function of the PROX1 transcription factor in malignant glioma. , 2015, , .		0
103	Validation of a 3-gene signature and development of an authentic cohort database to improve overall survival prediction and clinical treatment decision for patients with newly diagnosed prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5047-5047.	0.8	0